Substrate reduction properties of dinitrogenase activated in vitro are dependent upon the presence of homocitrate or its analogues during iron-molybdenum cofactor synthesis.
(R)-2-Hydroxy-1,2,4-butanetricarboxylic acid [(R)-homocitrate] has been has been recently reported to be an integral constituent of the otherwise thought to be inorganic iron-molybdenum cofactor of dinitrogenase [Hoover, T.R., Imperial, J., Ludden, P.W., & Shah, V.K. (1989) Biochemistry 28,2768-2771]. Different organic acids can substitute for homocitrate in an in vitro system for iron-molybdenum cofactor synthesis and incorporation into dinitrogenase [Hoover, T.R., Imperial, J., Ludden, P.W., & Shah, V. K. (1988) Biochemistry 27, 3647-3652]. Dinitrogenase activated with homocitrate-FeMo-co was able to reduce dinitrogen, acetylene, and protons efficiently. Homoisocitrate and isocitrate dinitrogenases did not reduce dinitrogen or acetylene, but showed very high proton reduction activities. Citrate and citramalate dinitrogenases had very low dinitrogen reduction activities and intermediate acetylene and proton reduction activities. CO inhibited proton reduction in both these cases but not in the case of dinitrogenases activated with other homocitrate analogues. By use of these and other commercially available homocitrate analogues in the in vitro system, the structural features of the homocitrate molecule absolutely required for the synthesis of a catalytically competent iron-molybdenum cofactor were determined to be the hydroxyl group, the 1- and 2-carboxyl groups, and the R configuration of the chiral center. The stringency of the structural requirements was dependent on the nitrogenase substrate used for the assay, with dinitrogen having the most stringent requirements followed by acetylene and protons.
Imperial
J
J
Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin, Madison 53706.
Hoover
T R
TR
Madden
M S
MS
Ludden
P W
PW
Shah
V K
VK
D001419:Bacteria / Q000032:analysis* / Q000201:enzymology; D002951:Citrates / Q000494:pharmacology*; D017037:Dinitrogenase Reductase; D004789:Enzyme Activation / Q000187:drug effects; D005288:Ferredoxins / Q000096:biosynthesis* / Q000378:metabolism*; D007536:Isomerism; D008956:Models, Chemical; D015394:Molecular Structure; D008983:Molybdoferredoxin / Q000096:biosynthesis*; D013379:Substrate Specificity / Q000187:drug effects
D002951:Citrates; D017037:Dinitrogenase Reductase; D005288:Ferredoxins; D008983:Molybdoferredoxin